20481-15-6

Basic information

• Product Name: ETHYL 4-CHLORO-1,3-DIMETHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE
• Synonyms: BUTTPARK 30\08-33;ETHYL 4-CHLORO-1,3-DIMETHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE;ETHYL 4-CHLORO-1,3-DIMETHYLPYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE;4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester;Ethyl 4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridine;ETHYL 4-CHLORO-5,7-DIMETHYLPYRAZOLO(3,4-B)PYRIDINE-3-CARBOXYLATE;Ethyl 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate ,97%
• CAS NO: 20481-15-6
• Molecular Formula: C₁₁H₁₂ClN₃O₂
• Molecular Weight: 253.68
• Mol File: 20481-15-6.mol

Chemical Properties

• Melting Point: 89-90°C
• Boiling Point: 356 °C at 760 mmHg
• Flash Point: 169.1 °C
• Appearance: /
• Density: 1.38 g/cm³
• Vapor Pressure: 3E-05mmHg at 25°C
• Refractive Index: 1.62
• PKA: 1.74±0.30(Predicted)
• CAS DataBase Reference: ETHYL 4-CHLORO-1,3-DIMETHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-CHLORO-1,3-DIMETHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE(20481-15-6)
• EPA Substance Registry System: ETHYL 4-CHLORO-1,3-DIMETHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE(20481-15-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 20481-15-6(Hazardous Substances Data)

Usage

Chemical Properties

Ginger solid

InChI:InChI=1/C11H12ClN3O2/c1-4-17-11(16)7-5-13-10-8(9(7)12)6(2)14-15(10)3/h5H,4H2,1-3H3

Upstream product

• 19736-06-2 4-hydroxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 3524-32-1 5-Amino-1,3-dimethylpyrazole 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 20481-33-8 diethyl 2-{[(1,3-dimethyl-1H-pyrazol-5-yl)amino]methylene}malonate 

Downstream Products

• 81153-35-7 1,6,8-Trimethyl-1,2-dihydro-6H-dipyrazolo[3,4-b;3',4'-d]pyridin-3-one 
• 287379-45-7 ethyl 4-[(4-fluorobenzenesulfonyl)methylamino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 175201-94-2 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 206258-48-2 ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 206258-44-8 ethyl 4-[benzyl-(4-methoxybenzene-sulfonyl)-amino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 1224440-81-6 GS⁽⁶⁴⁰⁾K₁₅₂₃A 
• 1224047-79-3 C₂₃H₂₁ClN₄O₂ 
• 1224047-80-6 C₁₈H₁₉ClN₄O 
• 1224047-77-1 C₁₇H₁₃Cl₂F₃N₄O 

Relevant articles and documents

Synthesis and characterization of new 1H-pyrazolo[3,4-b]pyridine phosphoramidate derivatives

Twelve new 1H-pyrazolo[3,4-b]pyridine phosphoramidate derivatives were synthesized under mild conditions by nucleophilic aromatic substitution reaction of aminoalkylphosphoramidates over 4-Cl substituted pyrazolo[3,4-b]pyridine in good yields. The new com

The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist

The identification of novel, potent, non-steroidal/small molecule functional GR antagonist GSK1564023A selective over PR is described. Associated structure-activity relationships and the process of optimisation of an initial HTS hit are also described.

SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV.

PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compounds disclosed hereinf having the structure of Formula 1: can be useful in the treatment, prevention, inhibiti

PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formura 1: can be useful in the treatment, prevention, inhibitio

New orally active PDE4 inhibitors with therapeutic potential

Structural optimization of pyrazolopyridine derivative 2, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was carried out successfully. The process of discovery of new orally active PDE4 inhibitors, which

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.

New orally active PDE4 inhibitors with therapeutic potential

The design, synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridine derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhib

Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors

Compounds of the formula which are useful in disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors

Potent and selective bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors were synthesized by a novel convergent route. Selectivity and efficacy versus MMPs and TACE could be controlled by appropriate substitution on the scaffolds and by variation of the P1′ group. Select compounds were found to be effective in in vivo models of arthritis.